Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice

BACKGROUND: Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied. METHODS: This is a mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Aviles Bueno, Beatriz, Soler, Maria Jose, Perez-Belmonte, Luis, Jimenez Millan, Anabel, Rivas Ruiz, Francisco, Garcia de Lucas, Maria Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/
https://www.ncbi.nlm.nih.gov/pubmed/35892023
http://dx.doi.org/10.1093/ckj/sfac096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/
https://www.ncbi.nlm.nih.gov/pubmed/35892023
http://dx.doi.org/10.1093/ckj/sfac096

Ejemplares similares